Diseño de un método de cultivo de organoides de miocardio derivados de células madre adultas

dc.contributorNeuta Arciniegas, Paola Andrea
dc.creatorQuesada Quintero, Fabio Andrés
dc.creatorGutiérrez Burgos, Isabella
dc.date.accessioned2022-06-02T15:16:52Z
dc.date.accessioned2022-09-22T18:35:50Z
dc.date.available2022-06-02T15:16:52Z
dc.date.available2022-09-22T18:35:50Z
dc.date.created2022-06-02T15:16:52Z
dc.date.issued2022-05-18
dc.identifierhttps://hdl.handle.net/10614/13944
dc.identifierUniversidad Autónoma de Occidente
dc.identifierRepositorio Educativo Digital
dc.identifierhttps://red.uao.edu.co/
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3454824
dc.description.abstractLos organoides son cultivos 3D desarrollados a partir de células madre creando un ambiente artificial propicio, en el cual las células pueden crecer e interactuar en un entorno tridimensional similar a las condiciones de un estado in vivo, imitando su funcionamiento molecular y celular lo cual permite tener un resultado en investigación de enfermedades y fármacos muy preciso. Para obtener un organoidese deben cultivar células madre en un medio favorable que permita su crecimiento y desarrollo. El propósito de esta investigación fue realizar el diseño de un método de cultivo que permita un adecuado entorno de crecimiento para el desarrollo de organoides de miocardio a partir de un cultivo de células madre mesenquimales (MSCs). Las células MSCs primero pasaron por un proceso de diferenciación acélulas endoteliales y cardiomiocitos que tarda entre 15 y 21 días respectivamente y posteriormente fueron utilizadas junto con hidrogel compuesto de colágeno como medio de cultivo para el desarrollo del organoides de miocardio. Los protocolos implementados para la gelificación del hidrogel fueron evaluados mediante la viabilidad celular del organoide al pasar 7 y 15 días de incubación, donde se realizó la observación de componentes de células vivas con pruebas de tinción supravital.
dc.description.abstractOrganoids are 3D cultures developed from stem cells, creating a favorable artificial environment in which cells can grow and interact in a three-dimensional environment similar to the conditions of an in vivo state, mimicking their molecular and cellular functioning, which allows for more accurate results in disease and drug research. To obtain an organoid, stem cells must be cultured in a favorable environment that allows their growth and development. The purpose of this research was to design a culture method that allows a suitable growth environment for the development of myocardial organoids from a culture of mesenchymal stem cells (MSCs). MSCs cells first undergo a differentiation process to endothelial cells and cardiomyocytes that can range from 15 to 21 days respectively, which are subsequently used together with collagen composite hydrogel as the culture medium for myocardial organoid development. The protocols implemented for the gelation of the hydrogel were evaluated by the cell viability of the organoid after 7 and 15 days of incubation, where the observation of live cell components was performed with supravital cell staining.
dc.languagespa
dc.publisherUniversidad Autónoma de Occidente
dc.publisherIngeniería Biomédica
dc.publisherDepartamento de Automática y Electrónica
dc.publisherFacultad de Ingeniería
dc.publisherCali
dc.relationQuesada Quintero, F.A. y Gutiérrez Burgos, I. (2022). Diseño de un método de cultivo de organoides de miocardio derivados de células madre adultas. (Pasantía de investigación). Universidad Autónoma de Occidente. Cali. Colombia
dc.relation[1] J. Drost and H. Clevers, “Translational applications of adult stem cell-derived organoids,” Development (Cambridge), vol. 144, no. 6, pp. 968–975, 2017, doi: 10.1242/dev.140566.
dc.relation[2] L. Grassi et al., “Organoids as a new model for improving regenerative medicine and cancer personalized therapy in renal diseases,” Cell Death and Disease, vol. 10, no. 3, 2019, doi: 10.1038/s41419-019-1453-0.
dc.relation[3] A. Skardal, T. Shupe, and A. Atala, “Organoid-on-a-chip and body-on-a-chip systems for drug screening and disease modeling,” Drug Discovery Today, vol. 21, no. 9, pp. 1399–1411, 2016, doi: 10.1016/j.drudis.2016.07.003.
dc.relation[4] J. Li et al., “Functional 3D Human Liver Bud Assembled from MSC-Derived Multiple Liver Cell Lineages,” Cell Transplantation, vol. 28, no. 5, pp. 510–521, 2019, doi: 10.1177/0963689718780332.
dc.relation[5] “Enfermedades cardiovasculares.” https://www.who.int/es/healthtopics/ cardiovascular-diseases#tab=tab_1 (accedido Feb. 28, 2022).
dc.relation[6] J. L. Manzini, “Declaración De Helsinki: Principios Éticos Para La Investigación Médica Sobre Sujetos Humanos,” Acta Bioeth, vol. 6, no. 2, pp. 321–334, 2000, doi: 10.4067/s1726-569x2000000200010.
dc.relation[7] K. E. Sung, X. Su, E. Berthier, C. Pehlke, A. Friedl, and D. J. Beebe, “Understanding the Impact of 2D and 3D Fibroblast Cultures on In Vitro Breast Cancer Models,” PLoS ONE, vol. 8, no. 10, pp. 1–14, 2013, doi: 10.1371/journal.pone.0076373.
dc.relation[8] “Boletin Observatorio Nacional de Salud.” https://www.ins.gov.co/Direcciones/ONS/Boletines/boletin_web_ONS/boletin 1.html (accedido Feb. 28, 2022).
dc.relation[9] R. E. Hynds and A. Giangreco, “Concise review: The relevance of human stem cell-derived organoid models for epithelial translational medicine,” Stem Cells, vol. 31, no. 3, pp. 417–422, 2013, doi: 10.1002/stem.1290.
dc.relation[10] B. Nugraha, M. F. Buono, and M. Y. Emmert, “Modelling human cardiac diseases with 3D organoid,” European Heart Journal, vol. 39, no. 48, pp. 4234–4237, 2018, doi: 10.1093/eurheartj/ehy765.
dc.relation[11] H. K. Voges, R. J. Mills, D. A. Elliott, R. G. Parton, E. R. Porrello, and J. E. Hudson, “Development of a human cardiac organoid injury model reveals innate regenerative potential,” Development (Cambridge), vol. 144, no. 6, pp. 1118–1127, 2017, doi: 10.1242/dev.143966.
dc.relation[12] H. D. Devalla and R. Passier, “Cardiac differentiation of pluripotent stem cells and implications for modeling the heart in health and disease,” Science Translational Medicine, vol. 10, no. 435, pp. 1–14, 2018, doi: 10.1126/scitranslmed.aah5457.
dc.relation[13] M. Zamani, E. Karaca, and N. F. Huang, “Multicellular Interactions in 3D Engineered Myocardial Tissue,” Frontiers in Cardiovascular Medicine, vol. 5, no. October, pp. 1–7, 2018, doi: 10.3389/fcvm.2018.00147.
dc.relation[14] A. I. Hoch and J. K. Leach, “Concise Review: Optimizing Expansion of Bone Marrow Mesenchymal Stem/Stromal Cells for Clinical Applications,” Stemcells Translational Medicine, vol. 3, no. 5, pp. 1–13, 2014, doi: 10.5966/sctm.2013- 0196.
dc.relation[15] M. F. Hoes, N. Bomer, and P. van der Meer, “Concise Review: The Current State of Human In Vitro Cardiac Disease Modeling: A Focus on Gene Editing and Tissue Engineering,” Stem Cells Translational Medicine, vol. 8, no. 1, pp. 66–74, 2019, doi: 10.1002/sctm.18-0052.
dc.relation[16] J. Kim, B. K. Koo, and K. J. Yoon, “Modeling host-virus interactions in viral infectious diseases using stem-cell-derived systems and CRISPR/Cas9 technology,” Viruses, vol. 11, no. 2, 2019, doi: 10.3390/v11020124.
dc.relation[17] S. D. Forsythe et al., “Environmental toxin screening using human-derived 3D bioengineered liver and cardiac organoids,” Frontiers in Public Health, vol. 6, no. April, 2018, doi: 10.3389/fpubh.2018.00103.
dc.relation[18] X. Yin, B. E. Mead, H. Safaee, R. Langer, J. M. Karp, and O. Levy, “Engineering Stem Cell Organoids,” Cell Stem Cell, vol. 18, no. 1, pp. 25–38, 2016, doi: 10.1016/j.stem.2015.12.005.
dc.relation[19] X. Qian, H. N. Nguyen, F. Jacob, H. Song, and G. L. Ming, “Using brain organoids to understand Zika virus-induced microcephaly,” Development (Cambridge), vol. 144, no. 6, pp. 952–957, 2017, doi: 10.1242/dev.140707.
dc.relation[20] K. Takahashi and S. Yamanaka, “Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors,” Cell, vol. 126, no. 4, pp. 663–676, 2006, doi: 10.1016/j.cell.2006.07.024.
dc.relation[21] D. E. Rodríguez-Fuentes, L. E. Fernández-Garza, J. A. Samia-Meza, S. A. Barrera-Barrera, A. I. Caplan, and H. A. Barrera-Saldaña, “Mesenchymal Stem Cells Current Clinical Applications: A Systematic Review,” Archives of Medical Research, vol. 52, no. 1, pp. 93–101, 2021, doi: 10.1016/j.arcmed.2020.08.006.
dc.relation[22] C. Bock et al., “The Organoid Cell Atlas,” Nature Biotechnology, vol. 39, no. 1, pp. 13–17, 2021, doi: 10.1038/s41587-020-00762-x.
dc.relation[23] S. Yamanaka, “Induced pluripotent stem cells: Past, present, and future,” Cell Stem Cell, vol. 10, no. 6, pp. 678–684, 2012, doi: 10.1016/j.stem.2012.05.005.
dc.relation[24] B. Nugraha, M. F. Buono, L. von Boehmer, S. P. Hoerstrup, and M. Y. Emmert, “Human Cardiac Organoids for Disease Modeling,” Clinical Pharmacology and Therapeutics, vol. 105, no. 1, pp. 79–85, 2019, doi: 10.1002/cpt.1286.
dc.relation[25] S. Bartfeld and H. Clevers, “Stem cell-derived organoids and their application for medical research and patient treatment,” Journal of Molecular Medicine, vol. 95, no. 7, pp. 729–738, 2017, doi: 10.1007/s00109-017-1531-7.
dc.relation[26] K. Thygesen et al., “Fourth universal definition of myocardial infarction (2018),” European Heart Journal, vol. 40, no. 3, pp. 237–269, 2019, doi: 10.1093/eurheartj/ehy462.
dc.relation[27] C. C. Veerman, G. Kosmidis, C. L. Mummery, S. Casini, A. O. Verkerk, and M. Bellin, “Immaturity of Human Stem-Cell-Derived Cardiomyocytes in Culture: Fatal Flaw or Soluble Problem?,” Stem Cells and Development, vol. 24, no. 9, pp. 1035–1052, 2015, doi: 10.1089/scd.2014.0533.
dc.relation[28] C. Jensen and Y. Teng, “Is It Time to Start Transitioning From 2D to 3D Cell Culture?,” Frontiers in Molecular Biosciences, vol. 7, no. March, pp. 1–15, 2020, doi: 10.3389/fmolb.2020.00033.
dc.relation[29] K. Duval et al., “Modeling physiological events in 2D vs. 3D cell culture,” Physiology, vol. 32, no. 4, pp. 266–277, 2017, doi: 10.1152/physiol.00036.2016.
dc.relation[30] L. L. Y. Chiu, K. Janic, and M. Radisic, “Engineering of oriented myocardium on threedimensional micropatterned collagen-chitosan hydrogel,” International Journal of Artificial Organs, vol. 35, no. 4, pp. 237–250, 2012, doi: 10.5301/ijao.5000084.
dc.relation[31] D. Egger, C. Tripisciano, V. Weber, M. Dominici, and C. Kasper, “Dynamic cultivation of mesenchymal stem cell aggregates,” Bioengineering, vol. 5, no. 2, pp. 1–15, 2018, doi: 10.3390/bioengineering5020048.
dc.relation[32] L. Alzamil, K. Nikolakopoulou, and M. Y. Turco, “Organoid systems to study the human female reproductive tract and pregnancy,” Cell Death and Differentiation, vol. 28, no. 1, pp. 35–51, 2021, doi: 10.1038/s41418-020-0565- 5.
dc.relation[33] J. A. Brassard and M. P. Lutolf, “Engineering Stem Cell Self-organization to Build Better Organoids,” Cell Stem Cell, vol. 24, no. 6, pp. 860–876, 2019, doi: 10.1016/j.stem.2019.05.005.
dc.relation[34] A. L. Caipa Garcia, V. M. Arlt, and D. H. Phillips, “Organoids for toxicology and genetic toxicology: applications with drugs and prospects for environmental carcinogenesis,” Mutagenesis, no. June, pp. 1–12, 2021, doi: 10.1093/mutage/geab023.
dc.relation[35] B. J. Haubner et al., “Functional Recovery of a Human Neonatal Heart after Severe Myocardial Infarction,” Circulation Research, vol. 118, no. 2, pp. 216– 221, 2016, doi: 10.1161/CIRCRESAHA.115.307017.
dc.relation[36] H. K. Voges, R. J. Mills, D. A. Elliott, R. G. Parton, E. R. Porrello, and J. E. Hudson, “Development of a human cardiac organoid injury model reveals innate regenerative potential,” Development (Cambridge), vol. 144, no. 6, pp. 1118–1127, 2017, doi: 10.1242/dev.143966.
dc.relation[37] E. R. Porrello and E. N. Olson, “A neonatal blueprint for cardiac regeneration,” Stem Cell Research, vol. 13, no. 3, pp. 556–570, 2014, doi: 10.1016/j.scr.2014.06.003.
dc.relation[38] M. Telsnig, “3-D Audio für Casinospielgeräte mittels Binauralsynthese und Übersprechkompensation Interner Projektbericht,” Audio, vol. 331, no. September, pp. 1078–1080, 2008, doi: 10.1126/science.1200708.Transient.
dc.relation[39] S. Schaaf et al., “Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology,” PLoS ONE, vol. 6, no. 10, 2011, doi: 10.1371/journal.pone.0026397.
dc.relation[40] E. R. Porrello et al., “Regulation of neonatal and adult mammalian heart regeneration by the miR-15 family,” Proc Natl Acad Sci U S A, vol. 110, no. 1, pp. 187–192, 2013, doi: 10.1073/pnas.1208863110.
dc.relation[41] Y. Petrenko, E. Syková, and Š. Kubinová, “The therapeutic potential of threedimensional multipotent mesenchymal stromal cell spheroids,” Stem Cell Research and Therapy, vol. 8, no. 1, pp. 1–9, 2017, doi: 10.1186/s13287-017- 0558-6.
dc.relation[42] I. A. Potapova, P. R. Brink, I. S. Cohen, and S. v. Doronin, “Culturing of human mesenchymal stem cells as three-dimensional aggregates induces functional expression of CXCR4 that regulates adhesion to endothelial cells,” Journal of Biological Chemistry, vol. 283, no. 19, pp. 13100–13107, 2008, doi: 10.1074/jbc.M800184200.
dc.relation[43] I. A. Potapova et al., “Mesenchymal Stem Cells Support Migration, Extracellular Matrix Invasion, Proliferation, and Survival of Endothelial Cells In Vitro,” Stem Cells, vol. 25, no. 7, pp. 1761–1768, 2007, doi: 10.1634/stemcells.2007-0022.
dc.relation[44] S. Acosta and V. Andrade, Manual de Esterilización para Centros de Salud. 2016. [Online]. Available: http://www1.paho.org/PAHOUSAID/ dmdocuments/AMR-Manual_Esterilizacion_Centros_Salud_2008.pdf
dc.relation[45] M. I. Melo, “Extracción, cultivo y caracterización de células mesenquimales de médula ósea en biodispositivos para la regeneración del miocardio infartado,” Trabajo de investigación. Fac. Ingeniería, Dpto de Electrónica y Automática, Prog. Ing Biomédica. Univ. Autonoma de occidente. Santiago de Cali, Valle, 2019
dc.relation[46] “Collagen Type I, Rat Tail | 3D Cell Culture Gels & Coating | ibidi.” https://ibidi.com/cell-culture-microscopy/107-collagen-type-i-rat-tail.html (accedido Apr. 26, 2022).
dc.relation[47] O. Pagliarosi, V. Picchio, I. Chimenti, E. Messina, and R. Gaetani, “Building an Artificial Cardiac Microenvironment: A Focus on the Extracellular Matrix,” Frontiers in Cell and Developmental Biology, vol. 8, no. September, pp. 1–8, 2020, doi: 10.3389/fcell.2020.559032.
dc.relation[48] C. Gardin, L. Ferroni, C. Latremouille, J. C. Chachques, D. Mitrečić, and B. Zavan, Recent Applications of Three Dimensional Printing in Cardiovascular Medicine, vol. 9, no. 3. 2020. doi: 10.3390/cells9030742.
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAtribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0)
dc.rightsDerechos reservados - Universidad Autónoma de Occidente, 2022
dc.subjectIngeniería Biomédica
dc.titleDiseño de un método de cultivo de organoides de miocardio derivados de células madre adultas
dc.typeTrabajo de grado - Pregrado


Este ítem pertenece a la siguiente institución